Is Crinetics Pharmaceuticals, Inc. (CRNX) Stock Positioned for Growth After Promising Atumelnant Clinical Results?

We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best biotech stocks on this list.

TheFly reported on June 14 that at ENDO 2026, CRNX presented Phase 2 data from its TouCAHn study evaluating investigational atumelnant in adults with classic congenital adrenal hyperplasia (CAH). The open-label trial assessed the once-daily oral ACTH receptor antagonist candidate, which is being developed for classic CAH and ACTH-dependent Cushing’s syndrome. Results from Cohort 4 showed that atumelnant enabled glucocorticoid dose reductions while maintaining androgen control. At week 12, participants experienced a 67% average reduction in morning serum androstenedione levels, with 7 of 8 patients reaching physiologic glucocorticoid dosing. The therapy was generally well tolerated, with no treatment-related severe or serious adverse events reported. The findings support continued development of atumelnant in later-stage clinical trials.

On the same day, it was reported that Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) presented updated long-term data from its PALSONIFY (paltusotine) clinical development program in acromegaly at ENDO 2026. Pooled results from the open-label extension studies of PATHFNDR-1 and PATHFNDR-2 showed that once-daily oral PALSONIFY maintained disease control and was well-tolerated after two years of treatment. In PATHFNDR-1, patients previously controlled on injectable SRLs maintained stable IGF-1 levels, symptoms, and tumor volume. PATHFNDR-2 showed reductions in IGF-1 levels among patients with uncontrolled acromegaly, with stable symptoms and tumor measurements. Across the pooled population of 167 patients, no new safety concerns were identified.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a commercial-stage pharmaceutical company developing novel treatments for rare endocrine diseases, including PALSONIFY (paltusotine), an approved therapy for related conditions.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.